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ABSTRACT A novel combination of experimental data and extensive computational modeling was used to explore probable
protein-protein interactions between photoactivated rhodopsin (R*) and experimentally determined R*-bound structures of the
C-terminal fragment of a-transducin (Gta(340-350)) and its analogs. Rather than using one set of loop structures derived from
the dark-adapted rhodopsin state, R* was modeled in this study using various energetically feasible sets of intracellular loop (IC
loop) conformations proposed previously in another study. The R*-bound conformation of Gta(340-350) and several analogs
were modeled using experimental transferred nuclear Overhauser effect data derived upon binding R*. Gta(340-350) and its
analogs were docked to various conformations of the intracellular loops, followed by optimization of side-chain spatial positions
in both R* and Gta(340-350) to obtain low-energy complexes. Finally, the structures of each complex were subjected to energy
minimization using the OPLS/GBSA force ﬁeld. The resulting residue-residue contacts at the interface between R* and Gta(340-
350) were validated by comparison with available experimental data, primarily from mutational studies. Computational modeling
performed for Gta(340-350) and its analogs when bound to R* revealed a consensus of general residue-residue interactions,
necessary for efﬁcient complex formation between R* and its Gta recognition motif.
INTRODUCTION
The photoreceptor of the eye, rhodopsin, is the prototypical
member of the vast family of G-protein coupled receptors
(GPCRs). More than 16,000 GPCRs across many different
genomes are known (GPCRDB; http://www.gpcr.org), and
GPCRs are the largest protein superfamily in humans (1).
GPCRs are integral membrane proteins that include seven
transmembrane helical stretches (TM helices) connected by
loops that form the intracellular (IC) and extracellular (EC)
domains, together with the fragments containing the N- and
C-termini. Generally, GPCRs are activated by extracellular
agonists. Binding an agonist leads to a conformational
change in the receptor that exposes an intracellular binding
site within the IC domain for its G-protein. Upon binding to
an activated GPCR, the heterotrimeric G-proteins dissociate
and generate complexes of b- and g-subunits, as well as
complexes of a-subunit with adenosine triphosphate (ATP),
which trigger a signaling cascade downstream (2). Currently,
over 50% of the drugs used in clinics target GPCRs (3),
making an understanding of the molecular interactions at
atomic resolution between GPCRs and their ligands, both
intra- and extracellular, extremely valuable.
The conformational change from the inactive (R) to
activated state (R* or metarhodopsin II (MII)) in rhodopsin is
initiated by a single photon of light of the correct wave-
length, rather than by binding an extracellular molecular
ligand. The photon is absorbed by the chromophore, cis-11
retinal, which is covalently bound to the side chain of K-296
in helix 7 (TM7). Isomerization of cis-11 retinal to the all-
trans isomer initiates a conformational change of the trans-
membrane helices that generates a binding site among the
IC loops for the heterotrimeric G-protein, transducin (4).
Transducin may be considered an intracellular ligand of
rhodopsin, as the C-terminal ends of transducin’s a- and
g-subunits (Gta and Gtg) directly interact with rhodopsin (5–8).
Some forms of visual impairment, such as congenital night
blindness (CNB) and retinitis pigmentosa, are due to muta-
tions in rhodopsin that lead to its constitutive activation, i.e.,
spontaneous transition from the dark-adapted (R) to acti-
vated (R*) state (2). Unlike other GPCRs, rhodopsin cannot
be targeted by blocking an extracellular ligand because its
‘‘ligand’’ is a photon; however, modulating the interaction
between activated rhodopsin and transducin in the eye with
an intracellular inhibitor, such as a small molecule pep-
tidomimetic of the C-terminal fragment of Gta, Gta(340-
350), could be a potential therapy for the above diseases. To
lay the foundation for the molecular design of intracellular
inhibitors that could prevent transducin from binding con-
stitutively active rhodopsin mutants, one must know which
speciﬁc residue-residue interactions occur between the IC
regions of rhodopsin and transducin.
The photoactivated state of rhodopsin (R*, MII) is sta-
bilized by interaction with the C-terminal undecapeptide
Gta(340-350) (6). The NMR studies of TrNOE (transferred
nuclear Overhauser effect) revealed three-dimensional (3D)
structure(s) of Gta(340-350) in complex with R* (6); similar
studies were also performed for several analogs of Gta(340-
350) (9–12). Therefore, the conformation of Gta(340-350)
may serve as a convenient model constraint for Gta in
complex with R*. The 3D structures of the IC segments of
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R* in complex with transducin are not known, however.
Although the X-ray structure of rhodopsin has been solved,
the structures of the IC loops and the C terminus are either
poorly resolved, or contradictory, in different structures
obtained by x-ray crystallography (13–16), due to the
inherent ﬂexibility of the IC region. Further, the x-ray struc-
tures of rhodopsin were originally determined for the dark-
adapted state that does not interact with transducin, whereas
the rhodopsin-transducin complex involves the photoacti-
vated MII state of rhodopsin. Recently, the x-ray crystal
structure of the photoactivated MII state of rhodopsin has
been solved (17). This structure conﬂicts, however, with a
large amount of biophysical data that suggest more move-
ment of certain transmembrane helices as a result of the
conformational change associated with the transition from
R/R*. This discrepancy leads to ambiguities as to whether
this crystal structure reﬂects the true state of R* that binds
transducin, despite the MII spectral intermediate being
observed in the crystal. Further, this x-ray crystal structure
was solved at only 4.15 A˚ resolution with several regions on
the intracellular loops unresolved, so precise positions of
amino acids and some loop positions were not discernable.
At the same time, the arrangement of the TM helices in the
R* state of rhodopsin was suggested by the ESR (electron
spin resonance) spectroscopy (4) and by independent mole-
cular modeling (18). Subsequent modeling studies, based on
the 3D models for the TM region corresponding both to the
R and R* states, revealed possible low-energy structures of
the ﬂexible EC and IC loops in rhodopsin (19). In this study,
the experimental TrNOE structures of Gta(340-350) and
several of its analogs were docked to various low-energy
structures for the IC region of rhodopsin in the activated R*
state to determine possible residue-residue interactions be-
tween the two molecules upon forming the complex. Since
all these peptides of similar structure stabilize MII and bind it
with comparable afﬁnities (Table 1), it was logical to hypo-
thesize that they possess a common binding mode in the
complex with the IC region of the R*. Accordingly, our
objective in this study was to elucidate residue-residue inter-
actions that are most important for mutual molecular recog-
nition of R* and the peptide analogs experimentally studied.
This study takes a novel prospective in considering multiple
sets of low-energy loop conformations, whereas other stud-
ies have only considered one conformation of loops derived
from the R state. Further, this methodology combines experi-
mental data of the R*-bound conformation of several peptide
ligands with extensive computational modeling to determine
the important residue-residue interactions in the complex.
Targeting these interactions should assist in the design of
effective intracellular inhibitors to treat certain types of con-
genital visual impairment.
METHODS
3D models of molecular fragments
Models for the IC loops of rhodopsin
3D models of the rhodopsin loops used in this study were adopted from the
intracellular (IC) loop models built by Nikiforovich and Marshall (19),
where the ensemble of intracellular loops was mounted on the 3D model of
the rhodopsin transmembrane domain in its activated conformation (R*).
Each set of the IC loops consisted of four molecular segments, namely the
three loops connecting TM1 and TM2 (IC1, fragment 61-75), TM3 and TM4
(IC2, fragment 136-153), and TM5 and TM6 (IC3, fragment 222-249) as
well as the fragment 303–322 that included the part of the C-terminal helix
parallel to the membrane surface (IC4). The loops included stems of TM
helices (fragments 61-63, 73-75, 136-138, 151-153, 222-224, 247-249, and
303-305, respectively) that were kept in the same spatial positions as they
were in the transmembrane domain by a system of parabolic potentials
(see (19) for details). At the base of the TM stems, where the transmem-
brane domain is normally located, the artiﬁcial N- and C-termini were
capped with acetyl and NHMe, respectively. In total, nine sets of the
IC11IC21IC31IC4 loop ‘‘packages’’ that differ in their backbone con-
formations by a root mean-square (RMS) value of at least 3.0 A˚ (Ca atoms
only) (19) were used in subsequent calculations to simulate backbone ﬂexi-
bility in the IC loops. Finer sampling was done by using structures within
one of the nine sets of loop conformers that were found to be signiﬁcant.
Models for Gta(340-350) and analogs
Besides Gta(340-350), ﬁve other analogs of the undecapeptide that showed
binding to R* comparable to that of Gta(340-350) were considered in this
study (Table 1). Four of the analogs, peptide 2, peptide 11, peptide 14, and
peptide 3 (denoted according to Anderson et al. (9,10)), differed from
Gta(340-350) by modiﬁcations in the last residue and C-terminal end, and
the ﬁfth analog was [R341, S347]-Gta(340-350). The TrNOE structures of
native Gta(340-350) and its analogs that were used as the 3D models in
subsequent docking calculations were borrowed from the following sources:
Gta(340-350), PDB entry 1AQG (6); peptide 14 (9); peptide 3 (10); and
[R341, S347]-Gta(340-350), PDB entry 1LVZ (12). The sets of structures
deduced for Gta(340-350) and its ﬁve analogs by TrNOE were subjected to
limited energy minimization using the Optimized Potential for Liquid
Simulations (OPLS)-AA-L/ Generalized Born Solvation Approximation
(GBSA) force ﬁeld in the TINKER modeling software (20), and the local
minimum energy structure found was used in subsequent docking calcu-
lations. The OPLS-AA-L force ﬁeld was chosen because its parameters were
optimized for use with peptides and proteins (21). Peptides 2 and 11 had
similar binding afﬁnities, but their TrNOE structures were not available. For
these two analogs, the 3D structures were constructed in the SYBYL
modeling package by modifying the 3D structure of Gta(340-350) and
subjected to energy minimization using the Tripos force ﬁeld. Subsequently,
peptides 2, 11, 14, 3, [R341, S347]-Gta(340-350), and Gta(340-350) were
all subjected to the same docking procedures. The N- and C-termini of the
peptides were modeled with an amino group (NH2) and a carboxyl group
(COOH) or carboxamido group (CONH2) (Table 1), so there was no net
TABLE 1 Intracellular ligands of rhodopsin considered in this
study and their binding afﬁnities to rhodopsin
Peptide Sequence EC50 6 SE (mM) Reference
Gta(340-350) IKENLKDCGLF-OH 530 6 90 (9)
Peptide 2 IKENLKDCGLW-OH 540 6 50 (9)
Peptide 11 IKENLKDCGL(2-Nal)-NH2 220 6 70 (9)
Peptide 14 IKENLKDCGLF-NH2 320 6 70 (9)
Peptide 3 IKENLKDCGLX* 600 6 90 (10)
[R341, S347]-
Gta(340-350)
IRENLKDSGLF-OH . 1000y (42)
*X indicates a phenylethylamine derivative.
yThe EC50 value was measured on an acetylated peptide.
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charge at the ligand termini. In separate calculations, the N- and C-termini of
the relevant peptides were modeled with charged amino (NH13 ) and carboxyl
groups (COO).
Models of crystal structures used for validation
The following set of high-resolution crystal structures of complexes was
used for validation of the employed docking protocol: HLA/peptide (the
PDB entry 2BVO), BclXL/Bak (1BXL), MDM2/p53 (1T4F), and CheY/
FLIM (1F4V). 2BVO contains the largest and most distinct binding cavity,
whereas 1F4V has the shallowest cavity. To maintain uniformity and insure
force-ﬁeld self-consistency with the loop structures obtained using rigid-
valence geometry (see (19)), the experimental crystal structures were adjusted
to the same rigid-valence geometry constraints before starting the docking
procedure by applying a system of harmonic potentials. The resulting struc-
tures were very close to the initial crystal structures, with the RMS values
,0.75 A˚ for Ca atoms only.
Docking procedures
Low-resolution docking search
The GRAMM (Global RAnge Molecular Matching) docking protocol (ﬁrst
described in (22)) was used to obtain the initial docked poses of the
‘‘ligand’’ (various NMR structures determined by TrNOE) relative to the
‘‘receptor’’ (the set of the IC loops of rhodopsin) (Fig. 1 A). GRAMM
predicts the docking conformation by maximizing the 3D overlap of surfaces
of two molecules using a fast Fourier transformation (22–24). We used the
low-resolution GRAMM protocol (24) that calculates the corresponding
scoring function on the six-dimensional grid with translational steps of 3 A˚
and rotational steps of 20. The speciﬁc parameters for the GRAMM pro-
cedure were as follows: grid step  3.0, repulsion  6.5, attraction  0.0,
potential range type – grid_step, projection – gray, representation – all, angle
for rotations 20. The GRAMMmodule was downloaded from the Internet
site http://vakser.bioinformatics.ku.edu. For each ligand-receptor complex,
999 conﬁgurations corresponding to the top values of the scoring function
were retained for further consideration.
High-resolution docking search
The top 999 solutions (spatial positions of the rigid ligand with respect to
R*) obtained by the GRAMM procedure were divided into clusters that
differed by RMS values,3 A˚ in their spatial location (the RMS values were
calculated for the backbone atoms, excluding hydrogens) (Fig. 1 B). The
solution with the best GRAMM score within each cluster was optimized
further in two separate steps (Fig. 1 C). First, the relative spatial positions of
the ligand and IC loops of rhodopsin were adjusted and the side chains were
repacked; at this step, conformations of the peptide backbone in both
molecular entities were not affected. The above procedure employed a
methodology similar to that used previously to optimize spatial locations of
the TM helices in the heptameric bundle (18). Brieﬂy, the methodology
involved energy minimization of the two molecules to optimize their mutual
spatial arrangement as rigid bodies. The rigid-body optimization allowed
both the ligand and the loop entities to translate along and rotate about the x,
y, and z coordinate axes. At each recalculation of the energy gradient, side-
chain repacking was done by an algorithm developed earlier that employed
an option of a step-wise grid search (25), with the step size of 30. The
ECEPP/2 force ﬁeld, which assumed rigid-valence geometry, was used in
these calculations. Only the trans-conformation of Pro was used in the
calculations, and residues Arg, Lys, Glu, and Asp were modeled as charged
species. The value of the dielectric constant was equal to 2, which is
considered standard for a protein environment modeled with the ECEPP
force ﬁeld. The energy tolerance for minimization convergence was DE ,
0.1 kcal/mol, and the tolerance for translational and rotational coordinates
was 0.1 A˚ and 0.1 respectively.
Second, after repacking the side chains and performing rigid-body
optimization, the resulting structures were subjected to energy minimization
using the OPLS-AA-L/GBSA force ﬁeld as implemented in TINKER (20).
The structure was subjected to preliminary energy minimization to 1.0 A˚
RMS using the minimize function (L-BFGS minimization), followed by
energy minimization to 0.1 A˚ RMS using the truncated Newton method in
TINKER. The TINKER molecular modeling package can be downloaded
from the Internet site http://dasher.wustl.edu/tinker. Spatial positions of the
three Ca atoms at the bases of the TM stems were ﬁxed during the mini-
mization. All other atoms, including the loop and ligand backbone atoms,
were allowed to move. TINKER contains bond lengths, angle bending, and
improper torsion angles for amino acids with charged termini. In this study,
neutral peptide termini were used, and parameters for bond lengths, angle
bending and improper torsion were derived from TINKER parameters for
charged termini. Some of the docked solutions were docked in very close
proximity to the receptor, causing some of the Born radii to be negative. The
following line was added to the born.f TINKER code (rborn(i) .lt. ri) rborn(i)¼
100.0d0 to turn off solvent screening if the Born radii became negative. The
structures were reranked according to the energies calculated using TINKER,
and only those with the relative energies E Emin , 30 kcal/mol were con-
sidered as viable solutions.
RESULTS
Validation of docking protocol at the known
protein-protein complexes
The docking protocol used in our study starts from a low-
resolution search by running GRAMM, a program that scans
the entire surface of a protein and scores each docked ligand-
protein complex. The program enumerates all docked con-
ﬁgurations within the accuracy of the grid-step size and
rotation-step size. In addition, all conﬁgurations were scored
based on complementary overlap of molecular surfaces,
providing a low-resolution scoring screen. The conﬁgura-
tions of the two molecules corresponding to the top scores
(;200 conﬁgurations after clustering) were subjected to a
high-resolution search by optimizing their rigid-body spatial
positions and re-packing their side chains, followed by a full
energy minimization procedure that allows selection of
conﬁgurations with relative energies ,30 kcal/mol from the
lowest energy structure. The advantages of this docking pro-
tocol are the systematic search of the conﬁgurational space
about the ligand-protein complex; the ability to repack side
chains in both ligand and protein; and the ability to perform
docking fast and within rather modest available computa-
tional resources (the complete studies for the Gta(340-350)-
rhodopsin complex, as described below, required ;35 days
on a single node PC with 2.8 GHz under the Linux operating
system). The exact runtime is dependent on the number of
CPUs available, the number of clusters resulting from the
GRAMM solutions, and on the size of the proteins. The main
disadvantage of the method is that the rough grid and rigid-
body approximations used by the GRAMM procedure may
not contain the point closest to the lowest-energy solution;
however, this might be rectiﬁed by subsequent energy min-
imization. At the same time, employing the ﬁner grid would
exponentially increase the computer time required.
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Therefore, it was important to validate the docking proto-
col for several known complexes between proteins and their
peptide ligands (the PDB entries 2BV0, 1BXL, 1T4F and
1F4V). Generally, conﬁgurations selected by the docking
protocol include those where both the placement of the
docked ligand and the residue-residue interactions present in
the crystal structures of the validation complexes were recon-
structed. However, the degree of success varied between
different test cases. The closest similarity between docked
conﬁgurations and the crystallographic data was character-
ized by the RMS values (all ligand backbone atoms, ex-
cluding hydrogens) of 1.80 A˚ (2BV0), 2.58 A˚ (1BXL), and
3.39 A˚ (1T4F); in the case of 1F4V, the closest RMS value
was larger than 6 A˚. The RMS values when considering all
heavy atoms was not very different from the analysis with
just backbone heavy atoms: 2.08 A˚ (2BVO), 2.96 A˚ (1BXL),
3.70 A˚ (1T4F). The slight difference in RMS between only
the backbone versus all heavy atom RMS is relatively small,
indicating that the side chains are roughly in the same
conformations as the crystal structure. To determine if this
level of similarity would be sufﬁcient for the goals of our
study in which we are elucidating the system of ligand-
protein residue-residue interactions, the contacts between the
side chains of the ligands and proteins were determined. A
contact was deﬁned as spatial positioning of any two atoms
(including hydrogen atoms) belonging to different side
chains with a distance ,5.5 A˚. Fig. 2 illustrates similarities
and differences for the systems of residue-residue interac-
tions in the crystal structures of 2BV0, 1BXL, and 1T4F and
those found by the docking protocol.
Fig. 2 shows generally good consistency in the systems of
residue-residue contacts between the x-ray structures and the
closest structures found by the docking protocol. In all three
cases, many of the existing contacts were predicted correctly
(those marked in black in Fig. 2). Notably, the false positives
(contacts predicted by the protocol that were not in the
crystal structure, gray in Fig. 2) are almost always located
next to the correctly predicted contacts or to the false
negatives (contacts present in the crystal structure that the
protocol missed, cross). As one would expect, the structure
with the closest RMS value to the crystal structure found for
2BV0 had more correctly predicted residue-residue interac-
tions; in fact, out of 61 contacts existing in 2BV0, 46 (75%)
were predicted correctly, 15 were missed, and 13 were false
positives. Of those residue-residue interactions predicted
correctly, 30 are direct interactions (65%), a direct contact
being deﬁned as side chains on both the ligand and receptor
in nearly the same conformation and making a similar type of
interaction (hydrogen bonding, van der Waals, etc.) based onFIGURE 1 Flow chart of the docking procedure. (A) Low-resolution
docking, which involved the GRAMM program. (B) The solutions from
GRAMM were clustered at 3 A˚. (C) High-resolution docking, which
included an iterative rigid body and side-chain optimization followed by
minimization. (D) Distance cutoffs were imposed. (E) Energy cutoffs were
imposed.
FIGURE 2 Residue-residue contacts for the three ligand-protein com-
plexes used to evaluate docking methods. Residue-residue interactions
present in both the x-ray crystal structures and in the closest docked models
are shown in black. False negatives are shown with a cross, and false
positives are shown in gray.
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visual inspection. In fact, if the deﬁnition of a contact is
reduced to spatial positioning of any two atoms (including
hydrogen atoms) belonging to different side chains with a
distance ,4.0 A˚, we end up with only slightly more direct
contacts (74%) out of those residue-residue interaction pre-
dicted correctly.
Based on the above results, one can conclude that the
docking protocol works best for placing a ligand in a distinct
hole or cavity, as in the case of 2BV0. Interactions in this
HLA-peptide complex are somewhat analogous to those in
the R*-transducin complex, because the IC region of rho-
dopsin also possesses a cavity into which the ligand can
ﬁt. In other cases, where the x-ray complexes did not have
nearly as large a cavity or groove as did the HLA-peptide and
R*-transducin complexes, the protocol reproduced crystal-
lographic residue-residue interactions with lower, but still
reasonable accuracy. The methodology failed in the case of
CheY/FLIM peptide (1F4V), where the binding groove is the
most shallow; given the large binding cavity within the R*
loops, this was not a problem likely to be encountered,
however, when Gta(340-350) was docked to the IC loops.
Docking of Gta(340-350) and its analogs to the IC
region of R*
For Gta(340-350) and all other ligands, the GRAMM pro-
cedure (Fig. 1 A) was run on the one representative con-
formation for each of the nine sets (clusters) of possible R*
IC loop structures deduced previously (19). The top 999
solutions were taken from the GRAMM output of each run.
For ﬁve of the sets of IC loop structures, at least some of the
GRAMM solutions (7.2% to 97.8%, depending on the loop
structure) were located in the cavity formed by the R* loops.
However, some loop structures were too conﬁned to yield a
signiﬁcant number of GRAMM solutions that located the
ligand in the cavity; rather, artifact solutions corresponding
to conﬁgurations of the ligand positioned where the trans-
membrane domain was located were obtained. These loop/
peptide conﬁgurations were eliminated from further consid-
eration in the study of Gta(340-350) analogs. Obviously, the
remaining sets of the loop structures were the more ‘‘open’’
ones compared to the others. The ligand conﬁgurations cor-
responding to these sets of the loop structures were divided
into clusters according to the RMS value of 3 A˚ (Fig. 1 B, see
Methods), resulting in;200 clusters for each loop structure.
The conﬁgurations with the best GRAMM score for each
cluster were run through an optimization procedure, which
iteratively optimized the position of the ligand and the IC
region of rhodopsin as rigid bodies and then optimized side-
chain positions by repacking both ligand and receptor (Fig.
1 C). The resulting conﬁgurations were then subjected to
energy minimization employing the OPLS-AA-L/GBSA
force ﬁeld in the TINKER package. Energy minimization at
this stage removed small steric clashes and also permitted the
backbone to relax, providing some amount of backbone
ﬂexibility in both the receptor and ligand at this later stage of
the process to further optimize the complex.
Finally, two ﬁlters were employed to select viable solu-
tions of the entire procedure. The ﬁrst ﬁlter took advantage of
the rhodopsin site-directed mutagenesis data that revealed
fragments important for transducin binding, namely 136-139
(Y-136, V-137, V-138, V-139 in IC2); 247-249 (E-247,
K-248, E-249 in IC3); and 310-312 (N-310, K-311, Q-312 in
IC4) (Fig. 1 D) (26–28). Accordingly, only conﬁgurations
where the ligand made contact with one or more of these
residues in each loop were retained for further consideration.
A contact was deﬁned by at least one atom belonging to the
ligand and one atom belonging to protein, both of which
could be a hydrogen atom, located within a maximum dis-
tance of 4 A˚. Second, of the conﬁgurations from the ﬁrst
ﬁlter, only conﬁgurations with the relative energy E  Emin
, 30 kcal/mol (where Emin was the lowest energy across all
sets of the loop structures of solutions that met the ﬁrst
criteria, shown in Fig. 1 E) were considered viable (from 14
to 47 conﬁgurations for various ligands).
Common binding mode for Gta(340-350) and
its analogs
The main hypothesis of this study presumed the possibility
of a common binding mode for all discussed ligands with the
IC region of the photoactivated rhodopsin. To compare all
selected conﬁgurations for each peptide to each other, the set
of the loop structures was superimposed using the last three
Ca atoms in the TM stems. The RMS values for all backbone
atoms, excluding hydrogens, of the ligand were calculated.
The most similar conﬁgurations differed in spatial positions
of the ligand (relative to spatial position of Gta(340-350)) by
RMS values of 2.49–4.03 A˚ (Fig. 3). However, in terms of
spatial positions of the IC loops, all of them corresponded to
the same set of the loop structures, namely, the most ‘‘open’’
one. Interestingly, the same set of the loop structures per-
sisted in the similar conﬁgurations upon increasing the RMS
cutoff value up to 4.3 A˚. For several analogs, the preference
for this loop structure persisted with an RMS cutoff value
above 6 A˚. In other words, our results elucidated not only the
common binding mode for the ligands in the complex with
R*, but also the set of the 3D structures of the IC loops of R*
characteristic for the complex. We also did ﬁner sampling for
all six loop conformations comprising this set (see (19)). The
Gta(340-350) peptide was docked onto each of these loop
structures, and the common binding pose occurred on an
additional loop structure with an RMS of 3.629 A˚ that makes
the same important residue-residue interactions found for the
common binding mode with the exception of the interaction
between Lys-341 and Thr-70. This demonstrates that slight
variations in the loop structure can still yield this common
binding pose.
Differences in spatial positions of the ligand peptide back-
bones shown in Fig. 3 may seem signiﬁcant, but the systems
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of residue-residue interactions between Gta(340-350) and its
analogs with the IC loops were quite similar. Compared to
75 residue-residue contacts observed between Gta(340-350)
and R*, other ligands comprised 62–78 contacts, out of which
34–43 contacts were the same as observed for Gta(340-350).
Residues for which any loop atom was within 5.5 A˚ of any
ligand atom were considered to be interacting. Further, some
residue-residue interactions were common for all ligands
(Fig. 4). These interactions were as follows: Lys-341/
Thr-70, Phe-350/Leu-72, Phe-350/Val-137, Leu-349/
Lys-141, Leu-349/Lys-231, Cys-347/Gln-244, Leu-344/
Glu-249 (where transducin residues are shown in bold).
Ile-340/Gln-312 and Ile-340/Asn-315 interactions were seen
in all analogs except for Peptide 14. In our view, these par-
ticular residue-residue interactions are important targets for
drug design of compounds aimed at blocking G-protein bind-
ing to constitutively active rhodopsin mutants.
DISCUSSION
The molecular interactions by which the a-subunit of
transducin interacts with the set of the intracellular loops
of photoactivated rhodopsin (R*) remain elusive. The lack of
a crystal structure of the active complex has impeded the
understanding of this important interaction. Furthermore,
knowledge of the interaction of transducin with the IC region
of R* may yield additional insights into how other G-proteins
interact with their receptors in general and provide molecular
targets that will aid in the development of therapeutics for
eye diseases, such as retinitis pigmentosa and congenital
night blindness. By combining molecular modeling and ex-
perimental data, this study aimed to elucidate these important
residue-residue interactions between the C-terminal region
of transducin and the IC loops of R* using the TrNOE-
deduced structures of Gta(340-350) and its analogs. Several
sets of low-energy IC loop structures of R* were used in the
computational docking studies, unlike previous studies
(29,30) where single conformations of IC loops based on
the crystal structure of R were used. Given the conforma-
tional uncertainty of the IC and EC loops in the x-ray crystal
structure, we feel that this methodology provides a more
complete picture of potential residue-residue interactions
between R* and the C-terminal region of transducin. The
computational docking techniques used in this study allowed
us to explore the entire IC loop region rather than that in
molecular dynamics calculations where only a small region
of the receptor loop conﬁgurations could be explored.
This study determined a binding mode common for
Gta(340-350) and its analogs that have a comparable level of
afﬁnity to R*. It appeared that only the set of IC loop con-
formations of R* that corresponded to the most ‘‘open’’ con-
formation was relevant for this common binding mode.
Also, a rather limited pattern of residue-residue interactions
between R* and Gta was shown to be important for main-
taining the common binding mode. From the R* side, this
FIGURE 3 (A) Gta(340-350) and its analogs. (B) Peptide 2, (C) Peptide
11, (D) Peptide 14, (E) Peptide 3, and (F) [R341, S347]-Gta(340-350) are
shown in the common binding mode. The ﬁrst and last three Ca atoms in the
loop structures were superimposed to ﬁnd the common binding pose. IC1 is
shown in red, IC2 in yellow, IC3 in green and IC4 in blue. Gta(340-350) and
its analogs are shown in magenta. The ﬁgure was rendered in PYMOL
(DeLano Scientiﬁc, Palo Alto, CA).
FIGURE 4 Common residue-residue interaction at 5.5 A˚. Gta(340-350) is
shown in purple, IC1 in red, IC2 in orange, IC3 in green, and IC4 in blue.
Only side chains are shown. The side chains of residues involved in inter-
actions are rendered in ball-and-stick format to better illustrate the interaction.
All hydrogen atoms are omitted for clarity. The residues are labeled in cor-
responding color.
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pattern involved residues T-70, L-72, V-137, K-141, K-231,
Q-244, E-249; from the transducin side, it involved residues
K-341, L-344, C-347, L-349 and F-350 (see Fig. 4). As was
mentioned above, R* fragments 136-139, 247-249, and 310-
312 have been known to be important for transducin binding
by previous mutagenesis experiments (26–28). These frag-
ments were used in the ﬁltering procedure and have some
common residue-residue interactions among Gta(340-350)
and its analogs, namely V-137(IC2)-Phe-350 and E-249(IC3)-
L-344. The residue K-141 located in IC2 was not used in the
ﬁltering procedure and, therefore, was predicted as being
involved in the R*-transducin interaction; some experimen-
tal evidence conﬁrms that K-141 (31–33) and Q-244 (34) are
important for transducin binding. So far, there is no speciﬁc
experimental evidence of involvement of R*-residues T-70,
L-72 (IC1), and K-231 (IC3) in interactions with transducin,
which are predicted by this study.
Our selection procedure did not use any experimental
information as to which transducin residues are important for
interaction with R*. The complete site-directed mutagenesis
study of transducin has been performed by obtaining a series
of single alanine mutations to the a-subunit of transducin
(35). Some of the mutations that impaired the interaction
between transducin and R* were located on two different
fragments of Gta, namely on a region that binds the
bg-subunit and on a region that directly binds R*. Specif-
ically, seven residues on the C-terminal end of Gta impaired
the interaction with R* when they were mutated to alanine
(I-340, K-341, N-343, L-344, G-348, L-349, and F-350). In
the current study, all but one of the interactions that were
seen in the common binding mode with R* involved residues
(K-341, L-344, L-349, and F-350); these residues closely
correspond to the above experimental data. An interaction
with C-347 was also present in the common binding mode
(see Fig. 4), but mutation of C-347 to alanine was found to
have the overall wild-type phenotype in the discussed ex-
perimental study (35). However, in another set of experi-
ments performed with Gta(340-350) and its analogs,
mutating C-347 to serine caused transducin to completely
lose its ability to bind and stabilize the MII state of rhodopsin
(36). Further, when the sulfhydryl group on C-347 was
blocked by alkylation, very little stabilization of the MII state
was seen. In the same study, L-349 was also shown to be a
residue critical for interaction with rhodopsin, as syntheti-
cally changing this residue to Ile or tert-leucine caused a
signiﬁcant reduction in MII stabilization. One can conclude,
therefore, that all residues of Gta(340-350) predicted by our
study as involved in direct interaction with the IC region of
R* have been shown as important by experimental studies
(35,36). At the same time, none of the C-terminal transducin
residues experimentally found as not signiﬁcant for interac-
tion with R* (E-342, K-345, and D-346 (35)) were predicted
by these studies as involved in direct interaction with R*.
On the contrary, two 3D models of the transducin/
rhodopsin complexes developed by other authors suggested
rather different systems of residue-residue interactions be-
tween R* and Gta(340-350) (29,30). In the ﬁrst model, the
photoactivated state of rhodopsin was modeled by switching
the retinal chromophore to the all-trans conformation and
applying target-driven molecular dynamics with strict con-
straints to satisfy experimental distances between TM helices
in R* derived from spectroscopic data (29). Then, the 3D
crystal structure of trimeric transducin (utilizing the TrNOE-
deduced structure of Gta(340-350) to obtain coordinates for
residues 344-350) was manually docked to rhodopsin and
subjected to a long molecular dynamics simulation (;10 ns)
in a system that included the fully hydrated lipid bilayer.
Recently, the model was developed further to account for
possible oligomerization of the rhodopsin molecules (37).
The authors suggested the pattern of rhodopsin/transducin
residue-residue interactions that involved seven transducin
residues, K-341, L-344, K-345, D-346, C-347, L-349, and
F-350 (29), two of them (K-345 and D-346) were shown
with wild-type phenotypes when mutated to alanine (35).
The second model was built based on the assumed R* state
of the TM region of rhodopsin obtained by rotation of TM6
by;120 along the long axis (30). The model was packed in
an oligomeric structure that included four rhodopsin mole-
cules, one of them being R*. After manual docking of the 3D
model of the heterotrimeric transducin to R*, the entire sys-
tem was subjected to energy minimization (the model was
recently updated to accommodate the newly published x-ray
structures for dark-adapted rhodopsin (38)). In this model,
Gta(340-350) interacts with one R* molecule; according
to the authors, interaction involves residues K-341, E-342,
K-345, D-346, L-349, and F350 (30); this list, again, includes
residues K-345 and D-346 shown with wild-type phenotypes
when mutated to alanine (35). One more computational
model, which speciﬁcally addressed binding of Gta(340-
350), suggested that only the very C-terminal transducin
residues C-347- F-350 may directly contact residues of R*
(36); the contacts to R* of the last residues, C-347, L-349,
and F-350 were used in this model as requirements for
selecting possible binding modes of Gta(340-350) to R*.
The inclusion of these contact constraints in the predictions
of residue-residues contacts in the R*-transducin complex in
this study, not surprisingly, agree more closely to available
experimental data than the contacts suggested by other models.
In this study, we employed a combination of modeling
techniques, starting from a low-resolution search of possible
ligand-protein conﬁgurations by GRAMM, which exhaus-
tively samples the interface between the two molecules, to
a high-resolution search, which contains an optimization
feature (rigid-body optimization and side-chain repacking)
and a more accurate energy function implemented in the
TINKER package. Our modeling techniques possessed some
important advantages that allowed us to correctly predict
residue-residue interactions between Gta(340-350) and the
IC region of R*, as well as other experimental features of
the peptide(transducin)-R* complex. In our opinion, one of
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the advantages was that the GRAMM low-resolution search
method used in this study exhaustively evaluates possible
ligand positions about the protein, rather than employing a
stochastic search algorithm to sample conﬁgurational space,
as do most other docking techniques (39–41). Also, many
docking algorithms do not accommodate ligand/receptor in-
duced ﬁt by allowing the residues on the ligand and receptor
to repack after docking (40), whereas our docking meth-
odology optimized both rigid-body position and side-chain
orientations in both the ligand and receptor. This process
did not signiﬁcantly perturb the starting NMR structure of
Gta(340-350), as the common binding pose retained a con-
formation with a heavy atom backbone RMS of 1.003 A˚
and an all heavy atom RMS of 1.712 A˚. Throughout the
docking process, the crude-to-reﬁned docking method sig-
niﬁcantly reduced the number of docked structures that must
be considered and evaluated, allowing a more computation-
ally intensive energy function to be used on the remaining
structures. This methodology allowed us to explore the entire
surface of the receptor, rather than just a small region that
would have been explored with molecular dynamics calcu-
lations.
Other docking methods that provide ligand and/or recep-
tor ﬂexibility were tried. We tried using RosettaDock to dock
the Gta(340-350) TrNOE structure (Supplementary Mate-
rial). RosettaDock (39) uses a Monte Carlo sampling method
and allows ﬂexible side chains on both the ligand and
receptor. A global run failed to yield solutions that docked
within the receptor loops. The transmembrane domain was
added to our loop model, and the global run was repeated. A
clear energy funnel did not form, and there were no clear
clusters of ligand conﬁgurations that resulted from this
calculation. In addition, we also tried Autodock3.0, which
allows for varying degrees of ﬂexibility on the ligand, while
keeping the receptor side chains rigid (40). After trying many
variations of Autodock parameters using the Lamarkian
Genetic Search Algorithm (Supplementary Material), nearly
all the solutions from Autodock for Gta(340-350) and its
analogs failed to yield contacts between transducin and loop
residues of R* determined to be important in previous
mutational experiments.
Different options of the force ﬁeld parametrization (as ap-
plying charges to the peptide termini to produce a zwitter-
ionic molecule) also failed to determine the common binding
mode for all six ligands. Rather, ﬁve possible common
binding modes were seen in three of the analogs. One of the
ﬁve binding modes determined using the zwitterionic model
was the common binding mode found with the neutral pep-
tide termini. Using the zwitterionic model, this common
binding mode was seen for Gta(340-350), peptide 2, peptide
11, and 1LVZ. The effective dielectric within the loop region
of the rhodopsin receptor is not known, and therefore, adding
charges to the termini could yield artiﬁcially large electro-
static interactions that could potentially bias our model, so
we feel the neutral peptide model is more reliable.
The most unique aspect of this approach, however, was
not in the molecular modeling techniques. First, a variety of
possible conformations were considered for the IC loops of
rhodopsin in the photoactivated R* state (19), rather than fo-
cusing on one single conformation for the IC loops adopted
from the x-ray structure(s) for the R state as did others
(29,30,36–38). Given the fact that several low-energy con-
formations exist, all must be explored when building an
accurate model. Further, the conformations of IC loops in the
R x-ray crystal structure are unresolved, may not represent
the solution structure of the loops, and most likely do not
represent the loop structure of R* to which transducin or
Gta(340-350) binds. Second, our conclusions regarding the
3D structure of the peptide-R* complex were based on the
combined results obtained for several ligands; such consen-
sus may effectively increase the signal/noise ratio and cancel
minor errors that could occur in the case of any particular
ligand. Third, we focused on the pattern of residue-residue
interactions between Gta(340-350) and R*, which, on the
one hand, provides accuracy of predictions sufﬁcient for
further use in drug design, and, on the other hand, does not
require overinterpretation of site-directed mutagenesis data
in more rigorous (but often inappropriate) structural terms.
We believe that the novel elements of this computational
paradigmmay be useful for elucidating the patterns of residue-
residue interactions between extracellular ligands and their
receptors for other GPCRs belonging to the rhodopsin
family.
CONCLUDING REMARKS
In this study, we used a novel combination of computational
modeling, docking techniques, and experimental biophysical
data to elucidate the residue-residue interactions between the
possible structures of the ﬂexible intracellular loops of rhodop-
sin in the photoactivated state and the C-terminal fragment
of the a-subunit of transducin, Gta(340-350). Further, the
binding mode common for Gta(340-350) and its analogs was
identiﬁed. For the ﬁrst time, many low-energy intracellular
loop structures of R* were explored, making this study more
extensive than studies that only considered one intracellular
loop conformation based on R. Based on this study, it was
established that only one type of conformation of the IC
loops of R*, that corresponding to the most open structure,
bound Gta(340-350). This binding mode predicted a set of
residue-residue interactions between the two molecules that
was validated by previous data of site-directed mutagenesis
and other experimental studies. Since blocking the interac-
tion between R* and transducin could be important for
treating certain forms of visual impairment, these results may
be used to guide design of peptidomimetics or small
molecule drugs. Generally, the overall approach may also
be useful for studies of the interaction of other GPCRs with
their speciﬁc extracellular ligands.
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